CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
20.67
0.44%
Market Trading Hours* (UTC) Opens on Thursday at 14:30

Mon - Fri: 14:30 - 21:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading сonditions
Spread 0.11
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026151 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026151%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003929 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003929%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Exelixis Inc ESG Risk Ratings

High Medium Low Negligible

‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 20.58
Open* 20.67
1-Year Change* 18.59%
Day's Range* 20.53 - 20.69
52 wk Range 16.15-24.34
Average Volume (10 days) 2.57M
Average Volume (3 months) 46.99M
Market Cap 6.93B
P/E Ratio 79.36
Shares Outstanding 310.97M
Revenue 1.77B
EPS 0.28
Dividend (Yield %) N/A
Beta 0.54
Next Earnings Date Feb 6, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Feb 21, 2024 20.67 0.31 1.52% 20.36 20.72 20.35
Feb 20, 2024 20.58 0.25 1.23% 20.33 20.75 20.33
Feb 16, 2024 20.41 0.16 0.79% 20.25 20.78 20.25
Feb 15, 2024 20.54 0.29 1.43% 20.25 20.84 20.25
Feb 14, 2024 20.35 0.18 0.89% 20.17 20.52 20.14
Feb 13, 2024 20.17 0.01 0.05% 20.16 20.63 20.05
Feb 12, 2024 20.34 0.22 1.09% 20.12 20.37 19.96
Feb 9, 2024 20.16 -0.01 -0.05% 20.17 20.36 20.03
Feb 8, 2024 20.12 0.02 0.10% 20.10 20.60 20.06
Feb 7, 2024 20.10 -0.89 -4.24% 20.99 21.01 20.09
Feb 6, 2024 21.78 0.42 1.97% 21.36 21.84 21.36
Feb 5, 2024 21.35 0.18 0.85% 21.17 21.48 21.10
Feb 2, 2024 21.42 -0.16 -0.74% 21.58 21.66 21.29
Feb 1, 2024 21.69 0.31 1.45% 21.38 21.83 21.38
Jan 31, 2024 21.69 0.10 0.46% 21.59 22.00 21.59
Jan 30, 2024 21.82 0.01 0.05% 21.81 21.93 21.66
Jan 29, 2024 21.83 0.03 0.14% 21.80 21.96 21.69
Jan 26, 2024 22.04 -0.10 -0.45% 22.14 22.30 21.99
Jan 25, 2024 22.04 0.08 0.36% 21.96 22.40 21.76
Jan 24, 2024 22.06 -0.39 -1.74% 22.45 22.65 22.00

Exelixis, Inc. Events

Time (UTC) Country Event
Tuesday, April 30, 2024

Time (UTC)

10:59

Country

US

Event

Q1 2024 Exelixis Inc Earnings Release
Q1 2024 Exelixis Inc Earnings Release

Forecast

-

Previous

-
Thursday, May 30, 2024

Time (UTC)

16:00

Country

US

Event

Exelixis Inc Annual Shareholders Meeting
Exelixis Inc Annual Shareholders Meeting

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 1611.06 1434.97 987.538 967.775 853.826
Revenue 1611.06 1434.97 987.538 967.775 853.826
Cost of Revenue, Total 57.909 52.873 36.272 33.097 26.348
Gross Profit 1553.15 1382.1 951.266 934.678 827.478
Total Operating Expense 1409.58 1148.3 877.478 598.305 414.971
Selling/General/Admin. Expenses, Total 459.856 401.715 293.355 228.244 206.366
Research & Development 891.813 693.716 547.851 336.964 182.257
Unusual Expense (Income) 0
Operating Income 201.484 286.666 110.06 369.47 438.855
Interest Income (Expense), Net Non-Operating 33.065 7.672 19.865 27.959 12.84
Net Income Before Taxes 234.352 294.154 130.837 398.109 452.092
Net Income After Taxes 182.282 231.063 111.781 321.012 690.07
Net Income Before Extra. Items 182.282 231.063 111.781 321.012 690.07
Net Income 182.282 231.063 111.781 321.012 690.07
Income Available to Common Excl. Extra. Items 182.282 231.063 111.781 321.012 690.07
Income Available to Common Incl. Extra. Items 182.282 231.063 111.781 321.012 690.07
Diluted Net Income 182.282 231.063 111.781 321.012 690.07
Diluted Weighted Average Shares 324.556 322.359 318.001 315.009 312.803
Diluted EPS Excluding Extraordinary Items 0.56163 0.71679 0.35151 1.01906 2.20608
Diluted Normalized EPS 0.56163 0.71679 0.35151 1.01906 2.20608
Total Extraordinary Items
Dilution Adjustment 0
Other, Net -0.197 -0.184 0.912 0.68 0.397
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 469.848 408.788 423.917 411.738 419.427
Revenue 469.848 408.788 423.917 411.738 419.427
Cost of Revenue, Total 17.705 14.315 15.92 15.305 13.481
Gross Profit 452.143 394.473 407.997 396.433 405.946
Total Operating Expense 391.998 379.958 471.995 329.125 335.721
Selling/General/Admin. Expenses, Total 141.723 131.397 119.251 114.983 122.759
Research & Development 232.57 234.246 336.824 198.837 199.481
Operating Income 77.85 28.83 -48.078 82.613 83.706
Interest Income (Expense), Net Non-Operating 22.541 19.502 16.988 9.498 4.757
Other, Net -0.005 -0.054 -0.337 -0.069 0.045
Net Income Before Taxes 100.386 48.278 -31.427 92.042 88.508
Net Income After Taxes 81.178 40.028 -30.173 73.21 70.672
Net Income Before Extra. Items 81.178 40.028 -30.173 73.21 70.672
Net Income 81.178 40.028 -30.173 73.21 70.672
Income Available to Common Excl. Extra. Items 81.178 40.028 -30.173 73.21 70.672
Income Available to Common Incl. Extra. Items 81.178 40.028 -30.173 73.21 70.672
Diluted Net Income 81.178 40.028 -30.173 73.21 70.672
Diluted Weighted Average Shares 327.305 326.279 323.257 325.066 324.904
Diluted EPS Excluding Extraordinary Items 0.24802 0.12268 -0.09334 0.22522 0.21752
Dividends per Share - Common Stock Primary Issue 0 0 0 0 0
Diluted Normalized EPS 0.24802 0.12268 -0.09334 0.22522 0.21752
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 1618.76 1834.75 1445.4 1011.19 897.016
Cash and Short Term Investments 1308.47 1467.07 1206.54 852.243 693.334
Cash & Equivalents 501.195 647.169 319.217 266.501 314.775
Short Term Investments 807.273 819.905 887.319 585.742 378.559
Total Receivables, Net 214.784 282.65 160.875 120.173 178.827
Accounts Receivable - Trade, Net 214.784 282.65 160.875 120.173 162.771
Total Inventory 33.299 27.493 20.973 12.886 9.838
Prepaid Expenses 62.211 57.53 57.011 25.888 15.017
Total Assets 3071.49 2616.24 2137.33 1885.67 1422.29
Property/Plant/Equipment, Total - Net 345.435 149.153 110.394 90.727 56.764
Goodwill, Net 63.684 63.684 63.684 63.684 63.684
Long Term Investments 756.731 371.112 332.306 534.749 157.187
Other Long Term Assets, Total 285.218 195.878 185.554 185.32 247.635
Total Current Liabilities 324.359 337.59 204.658 142.746 105.472
Accounts Payable 32.667 24.258 23.632 11.581 10.901
Accrued Expenses 180.077 231.403 115.896 90.725 60.53
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 0.049
Other Current Liabilities, Total 111.615 81.929 65.13 40.44 33.992
Total Liabilities 583.062 405.624 258.22 199.7 134.833
Total Long Term Debt 0 0 0 0 0.079
Other Liabilities, Total 258.703 68.034 53.562 56.954 29.282
Total Equity 2488.43 2210.61 1879.11 1685.97 1287.45
Preferred Stock - Non Redeemable, Net 0 0 0 0
Common Stock 0.324 0.319 0.312 0.305 0.3
Additional Paid-In Capital 2536.85 2427.56 2321.9 2241.95 2168.22
Retained Earnings (Accumulated Deficit) -34.225 -216.507 -447.57 -559.351 -880.363
Other Equity, Total -14.521 -0.758 4.476 3.069 -0.701
Total Liabilities & Shareholders’ Equity 3071.49 2616.24 2137.33 1885.67 1422.29
Total Common Shares Outstanding 323.951 318.842 311.627 304.831 299.876
Other Current Assets, Total 0
Capital Lease Obligations 0.079
Property/Plant/Equipment, Total - Gross 406.307 189.984 145.078 116.287 74.073
Accumulated Depreciation, Total -60.872 -40.831 -34.684 -25.56 -17.309
Note Receivable - Long Term 1.659 1.665
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 1443.37 1590.53 1637.62 1618.76 1841.62
Cash and Short Term Investments 1103.39 1266.81 1313.13 1308.47 1546.99
Cash & Equivalents 396.859 464.48 540.597 501.195 675.286
Short Term Investments 706.528 802.335 772.536 807.273 871.706
Total Receivables, Net 248.113 232.818 233.923 214.784 215.015
Accounts Receivable - Trade, Net 248.113 232.818 233.923 214.784 215.015
Total Inventory 24.978 28.635 29.908 33.299 26.711
Prepaid Expenses 66.891 62.259 60.654 62.211 52.903
Total Assets 2976.91 3142.47 3143.36 3071.49 2961.37
Property/Plant/Equipment, Total - Net 121.039 115.004 116.212 110.624 107.909
Goodwill, Net 63.684 63.684 63.684 63.684 63.684
Long Term Investments 811.68 838.615 805.133 756.731 550.253
Other Long Term Assets, Total 536.503 533.382 519.325 520.029 397.541
Total Current Liabilities 376.816 339.617 327.597 324.359 301.733
Accounts Payable 26.45 25.994 32.621 32.667 30.572
Accrued Expenses 171.509 150.433 139.085 162.418 147.261
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 178.857 163.19 155.891 129.274 123.9
Total Liabilities 629.29 614.53 588.223 583.062 469.97
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 252.474 274.913 260.626 258.703 168.237
Total Equity 2347.62 2527.94 2555.14 2488.43 2491.4
Preferred Stock - Non Redeemable, Net 0 0 0 0 0
Common Stock 0.311 0.32 0.325 0.324 0.323
Additional Paid-In Capital 2487.37 2530.87 2558.3 2536.85 2512.67
Retained Earnings (Accumulated Deficit) -126.049 11.186 5.803 -34.225 -4.052
Other Equity, Total -14.012 -14.437 -9.289 -14.521 -17.538
Total Liabilities & Shareholders’ Equity 2976.91 3142.47 3143.36 3071.49 2961.37
Total Common Shares Outstanding 310.97 320.253 324.985 323.951 322.541
Note Receivable - Long Term 0.635 1.256 1.387 1.659 0.364
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line 182.282 231.063 111.781 321.012 690.07
Cash From Operating Activities 362.614 400.804 208.982 526.956 415.72
Cash From Operating Activities 20.875 13.63 9.141 8.348 4.915
Deferred Taxes -60.358 46.529 15.265 71.002 -244.111
Non-Cash Items 232.614 148.595 112.935 59.509 44.609
Cash Taxes Paid 127.87 12.96 4.115 7.873 10.677
Cash Interest Paid 0 0
Changes in Working Capital -12.799 -39.013 -40.14 67.085 -79.763
Cash From Investing Activities -524.414 -42.884 -131.215 -587.247 -297.85
Capital Expenditures -27.706 -64.225 -30.345 -12.834 -33.297
Other Investing Cash Flow Items, Total -496.708 21.341 -100.87 -574.413 -264.553
Cash From Financing Activities 0.586 -14.801 -25.132 12.553 9.691
Financing Cash Flow Items -23.3 -39.108 -50.018 -9.946 -7.574
Issuance (Retirement) of Stock, Net 23.886 24.307 24.886 22.499 17.278
Issuance (Retirement) of Debt, Net 0 -0.013
Net Change in Cash -161.214 343.119 52.635 -47.738 127.561
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line 40.028 182.282 212.455 139.245 68.573
Cash From Operating Activities 84.408 362.614 288.92 178.849 147.719
Cash From Operating Activities 6.855 20.875 14.929 9.266 4.49
Deferred Taxes 0 -60.358 0 0 15.318
Non-Cash Items 56.149 232.614 101.039 55.183 22.724
Changes in Working Capital -18.624 -12.799 -39.503 -24.845 36.614
Cash From Investing Activities -49.592 -524.414 -278.632 -209.681 -74.539
Capital Expenditures -12.024 -27.706 -25.989 -17.946 -5.609
Other Investing Cash Flow Items, Total -37.568 -496.708 -252.643 -191.735 -68.93
Cash From Financing Activities 4.586 0.586 2.589 4.627 0.205
Financing Cash Flow Items -2.557 -23.3 -16.091 -11.164 -4.686
Issuance (Retirement) of Stock, Net 7.143 23.886 18.68 15.791 4.891
Net Change in Cash 39.402 -161.214 12.877 -26.205 73.385
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 10.2899 32760974 -298694 2023-06-30 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 9.4881 30208283 -587233 2023-06-30 LOW
Farallon Capital Management, L.L.C. Hedge Fund 8.1223 25860000 2394000 2023-06-30 MED
Renaissance Technologies LLC Hedge Fund 4.6007 14647589 -631800 2023-06-30 HIGH
State Street Global Advisors (US) Investment Advisor/Hedge Fund 4.049 12891287 -66908 2023-06-30 LOW
JP Morgan Asset Management Investment Advisor 1.9022 6056306 73636 2023-06-30 LOW
Assenagon Asset Management S.A. Investment Advisor 1.8006 5732921 2315458 2023-06-30 HIGH
Meditor Capital Management Limited Investment Advisor 1.6131 5135758 -277142 2023-06-30 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.581 5033503 265404 2023-06-30 LOW
T. Rowe Price Associates, Inc. Investment Advisor 1.4901 4744230 -1037791 2023-06-30 LOW
Dimensional Fund Advisors, L.P. Investment Advisor/Hedge Fund 1.4811 4715692 62860 2023-06-30 LOW
Stephens Investment Management Group, LLC Investment Advisor 1.3078 4163863 89543 2023-06-30 LOW
First Trust Advisors L.P. Investment Advisor 1.274 4056102 -696632 2023-06-30 MED
Two Sigma Investments, LP Hedge Fund 1.2647 4026545 1429982 2023-06-30 HIGH
Jacobs Levy Equity Management, Inc. Investment Advisor/Hedge Fund 1.1752 3741606 -29298 2023-06-30 MED
Polar Capital LLP Investment Advisor/Hedge Fund 1.0431 3320898 0 2023-06-30 LOW
Point72 Asset Management, L.P. Hedge Fund 1.0398 3310580 -70159 2023-06-30 HIGH
Charles Schwab Investment Management, Inc. Investment Advisor 1.0294 3277320 39471 2023-06-30 LOW
Norges Bank Investment Management (NBIM) Sovereign Wealth Fund 0.9977 3176637 361504 2022-12-31 LOW
Nuveen LLC Pension Fund 0.9354 2978224 531596 2023-06-30 LOW

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Exelixis Company profile

Exelixis, Inc., a biotechnology company, engages in the discovery, development, and commercialization of new medicines to enhance care and outcomes for people with cancer. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. It also offers COTELLIC tablets, an inhibitor of MEK in combination with vemurafenib for the treatment of patients with BRAF V600E or V600K mutation-positive advanced melanoma in the United States; and in combination with vemurafenib in other territories, including the European Union, Switzerland, Canada, Australia, and Brazil. Exelixis, Inc. has collaboration and license agreements with Ipsen Pharma SAS, Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds and programs. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.
Industry: Bio Therapeutic Drugs

1851 Harbor Bay Parkway
ALAMEDA
CALIFORNIA 94502
US

Income Statement

  • Annual
  • Quarterly

News

Nvidia (NVDA) confronts high expectations for Q4 results

Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.

12:13, 20 February 2024

UK Bank Earnings: What to expect from Lloyds, Barclays and HSBC?

UK banks will be in the spotlight in the week ahead as the European earnings season continues

16:38, 16 February 2024

Is Big Tech behind the apparent bull market rally?

While the Magnificent Seven have dominated market momentum in recent months, it’s not true that they are the sole drivers of the recent rally in equity markets.

16:05, 8 February 2024

US Earnings Week Ahead: Walt Disney, Uber, and Pepsi Co.

The last of the Magnificent Seven have reported, delivering mixed results. Meanwhile, according to FactSet, the S&P 500 is set for negative earnings growth for Q4, with estimates for the next quarter also downgraded.

16:24, 2 February 2024

Bank of England preview: will updated projections show more cuts are expected in 2024?

Markets have no doubt that the BoE will keep its rate unchanged

15:43, 31 January 2024

Meta Platforms Q4 earnings forecast to surge on solid ad revenues

Meta Platforms (META) reports its Q4 results after Wall Street’s closing bell on February 1, 2024. We preview what to expect from the results and analyse the stock’s technicals.

15:33, 31 January 2024

Federal Reserve meeting preview: strong data is making it hard to justify cutting rates

Markets expect the Fed to keep rates unchanged as strong economic data continues

11:30, 30 January 2024

People also watch

XRP/USD

0.55 Price
-3.860% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.01168

Oil - Crude

78.03 Price
+1.000% 1D Chg, %
Long position overnight fee 0.0066%
Short position overnight fee -0.0285%
Overnight fee time 22:00 (UTC)
Spread 0.030

Gold

2,028.15 Price
+0.150% 1D Chg, %
Long position overnight fee -0.0188%
Short position overnight fee 0.0106%
Overnight fee time 22:00 (UTC)
Spread 0.30

US100

17,738.40 Price
+1.180% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0039%
Overnight fee time 22:00 (UTC)
Spread 1.8

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading